SUMMARY
INTRODUCTION
Epigenetic mechanisms such as DNA methylation and histone modification drive stable and clonally propagated changes in gene expression and have recently been shown to serve as molecular mediators of pathway dysfunction in neoplasia (Esteller, 2008; Rodríguez-Paredes and Esteller, 2011) . Indeed, both myelodysplastic syndrome (MDS) and leukemias are characterized by frequent epigenetic abnormalities and aberrant DNA hypermethylation has been linked to poor prognosis in cases of MDS, as it is associated with more rapid progression to acute myeloid leukemia (AML) (Shen et al., 2010; Shih et al., 2012) . Importantly, genome-wide discovery efforts in patients with myeloid malignancies have led to the identification of a number of causal genetic abnormalities that impact the epigenetic landscape. These genes include TET2, IDH1, IDH2, DNMT3a, and EZH2, all of which affect DNA and/or histone lysine methylation (Shih et al., 2012) .
Recent studies have examined in detail one such gene, TET2 (ten-eleven-translocation gene 2), which is located in 4q24 and whose mutation or deletion is extremely frequent in hematological malignancies, affecting 19% of patients with MDS, 12% of patients with myeloproliferative neoplasm (MPN), and 24% of patients with secondary AML Delhommeau et al., 2009; Jankowska et al., 2009; Tefferi et al., 2009) . TET2 mutations are observed in CD34 + progenitor cells and are detected most frequently after MPN and MDS progression to AML . TET2 catalyzes the oxidation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and is known to control hematopoiesis, presumably by regulating gene expression through its effect on DNA methylation (Branco et al., 2012; Ito et al., 2011; Ko et al., 2010; Shih et al., 2012) . Tet2 deficiency in mice impairs 5-mC hydroxylation and leads to skewed differentiation, as well as enhancement of the self-renewal and repopulating capacity of hematopoietic stem cells (HSCs). This in turn promotes malignant transformation in mice, causing disorders resembling MDS and MPN, as well as chronic myelomonocytic leukemia (CMMoL) (Moran-Crusio et al., 2011; Quivoron et al., 2011) . Recent studies have likewise shown that leukemia-associated Isocitrate Dehydrogenase (IDH) 1 or 2 mutant enzymes can induce carboxylation of glutamine-derived a-ketoglutarate (a-KG), with a concomitant increase in synthesis of 2-hydroxyglutarate (2-HG), an inhibitory metabolite of TET2 (Figueroa et al., 2010; Sasaki et al., 2012) . Collectively, these studies implicate functional and mutational losses of TET2 as key events underlying aberrant hematopoiesis and leukemogenesis, in turn suggesting that the inactivation of TET2 function by additional upstream cues could play a critical role in hematological malignancies.
MicroRNA (miRNA) deregulation is also known to contribute to hematological malignancies, including MDS and AML (Bartel, 2004; Chen et al., 2004; Gangaraju and Lin, 2009) . A combined approach involving assessment of miRNA expression (using microarrays) and bioinformatic prediction of mRNA targets has revealed that distinct miRNA signatures fine-tune each step of hematopoiesis, including the reconstitution potential of HSCs (Arnold et al., 2011; Gangaraju and Lin, 2009 ). In turn, miRNAs that target critical leukemia suppressors could act as powerful proto-oncogenes in the hematopoietic compartment (Calin and Croce, 2006) .
In this study, we demonstrate that miR-22 controls hematopoiesis and HSC maintenance by negatively regulating TET2 protein levels. Importantly, we identify miR-22 as an epigenetic modifier and the key oncogenic determinant for the pathogenesis of MDS and hematological malignancies in vivo, findings with prognostic and critical therapeutic implications for a large number of hematological disorders.
RESULTS

miR-22 Is Highly Expressed in Human Hematological Malignancies and Increases the Replating Ability of HSCs
In order to build on the insights of miRNA biology into epigenetic alterations in myeloid malignancies, we attempted to identify those miRNAs playing a critical role in the pathogenesis of the stem cell disorder MDS and its progression to overt leukemia. We first analyzed a previously reported miRNA microarray profiling database and found that miR-22 is markedly upregulated in patients with MDS (Figures S1A and S1B available online; Dostalova Merkerova et al., 2011) . These results prompted us to perform expression analysis by in situ hybridization in a large set of patient samples, which included bone marrow with no sign of disease (n = 37), early stage MDS (refractory anemia [RA] , 5q syndrome [5q-], refractory cytopenia with multilineage dysplasia [RCMD] , and RA with ringed sideroblasts [RARS]) (n = 40), and RA with excess blasts (RAEB) (n = 67). Our comprehensive in situ hybridization analysis revealed that miR-22 is highly expressed in patients with MDS ( Figure 1A and Figure S1C) . We next estimated the survival rates of the sets of MDS patients by using a Kaplan-Meier analysis and applied a log-rank test to compare the survival rates of MDS patients on the basis of miR-22 expression levels. Remarkably, we found that aberrant expression of miR-22 directly correlates with poor survival rates in patients ( Figure 1B) . It is noteworthy that the distribution of blasts into each World Health Organization (WHO) category of MDS stages was not directly associated with the expression level of miR-22, but a significant correlation between miR-22 levels and poor survival rates was observed within each WHO classification, as well as among MDS patients harboring a normal karyotype (Figures S1D-S1F ). This indicates that the poorer survival expectancy linked to miR-22 overexpression does not simply reflect confounding factors such as blast count and cytogenetic karyotype. Taken together, these findings led us to investigate the role of miR-22 in the hematopoietic system and the genesis of hematological malignancies.
To explore the function of miR-22 in hematopoiesis and leukemia, we first transduced mouse hematopoietic stem/progenitor cells (HSPCs; c-Kit pos Sca-1 pos Lin neg , hereafter referred to as KSL cells) isolated from wild-type donor mice with either a retroviral vector encoding miR-22 and a green fluorescent protein (GFP) or a control vector encoding GFP only. The GFP-expressing KSL cells were then resorted by flow cytometry and plated in methylcellulose for an in vitro colony-forming unit (CFU) assay ( Figure S1G ). We observed in the first plating that the cells expressing miR-22 produced fewer colonies compared to control cells; however, when GFP + KSL cells were resorted and replated, miR-22-transduced cells produced more colonies in the second plating ( Figure S1H ). Strikingly, these cells also maintained this ability throughout serial replatings: whereas control cells only formed colonies in the first two platings, miR-22-expressing KSL cells were able to produce colonies after being replated at least seven times ( Figure S1H ). Microscopic analysis of the cells from these colonies revealed a homogenous blast-like morphology (Figure S1I, top) . Consistent with these results, miR-22-expressing KSL cells maintained their characteristics and c-Kit expression (a marker of undifferentiated cells) during their replatings ( Figure S1I , bottom and Figures S1J and S1K). To ensure that miR-22-transduced and control cells were subjected to the same experimental treatment, we also performed an in vitro competitive colony assay by mixing GFP + KSL cells expressing miR-22 and GFP À control KSL cells (Figure S1L, top) . This analysis confirmed that miR-22-expressing GFP + , but not GFP À , KSL cells remained mostly in colonies through consecutive replatings ( Figure S1L , bottom). Taken together, these data suggest that miR-22 can drive aberrant replating capacity of HSPCs and may contribute to malignant transformation.
miR-22 Affects HSC Biology In Vivo
We next sought to examine the biological effects of miR-22 in vivo and generated a conditional transgenic mouse model overexpressing miR-22 in the hematopoietic compartment (Figure S2A ). miR-22 expression was induced by Mx1-Cre-mediated excision of a LoxP flanked transcriptional STOP cassette by administration of seven doses of polyinosine-polycytidine (pIpC) over 14 days (Figures S2B and S2C) . Two weeks after pIpC administration, we isolated KSL cells from miR-22
;Mx1-Cre mice and Mx1-Cre littermate controls and analyzed their properties by using CFU and long-term cultureinitiating cell (LTC-IC) assays ( Figures 1C-1G and Figure S2D ). In agreement with our previous retroviral transduction experiments, we found that KSL cells from miR-22 F/+ ;Mx1-Cre transgenic mice displayed an enhanced replating potential
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Regulation of TET2 by miR-22 in Hematopoiesis (Figures 1D and 1E) . Furthermore, ectopic expression of miR-22 caused a robust increase in the number of both KSL and mature myeloid cells, as determined by LTC-IC assay, indicating that miR-22 enhances HSPC maintenance and predisposes those cells to differentiate into the myeloid lineage ( Figures 1F and 1G ;Mx1-Cre mice exhibited a slight increase in chimerism compared to those from control animals ( Figure S2E ). Over time this difference became more pronounced as miR-22
;Mx1-Cre KSL cells outcompeted their wild-type counterparts (Figures 2A-2C and Figure S2F ). At (A) miR-22 is highly expressed in MDS patient samples. Expression levels of miR-22 in blasts in subtypes of MDS were measured by in situ hybridization analysis. Normal (n = 37), RA (n = 30), 5q-(n = 5), RCMD (n = 4), RARS (n = 1), RAEB-1 (n = 32), and RAEB-2 (n = 35) are shown. Representative images of in situ hybridization for miR-22 in MDS patients and normal bone marrow are also shown (left). Insets of panels show miR-22 staining in blasts (arrow with B) and in differentiated myeloid cells (e.g., neutrophil, arrow with M) with a high magnification. The expression levels of miR-22 were also scored as described in the Supplemental Experimental Procedures (right). The data were analyzed by Chi-square test. r, Pearson's r. Scale bars, 60 mm. (B) miR-22 overexpression correlates with poor survival rates of human MDS patients. MDS patients were divided into two groups; low-miR-22-expressing patients' group (miR-22 Score 1 or 2, n = 49, blue) and high-miR-22-expressing patients' group (miR-22 Score 3, n = 58, red). Overall survival of these patients is demonstrated. p value was generated by a log-rank test. ;Mx1-Cre mice or littermate controls were cultured in semisolid medium. Counting and classification of colonies were performed in independent littermate pairs (n = 3). GEMM, Colony-forming unit-granulocyte, erythroid, macrophage, and megakaryocyte; GM, Colony-forming unit-granulocyte and macrophage; M, Colony-forming unit-macrophage; E, Burst-forming unit-erythroid. (E) miR-22 expression retains the ability to serially replate and generate colonies. In vitro colony replating assay was performed as shown in Figure S2D and colony counts in the indicated replatings were scored (n = 3). N.D., nondetectable. 6 weeks posttransplantation, an increased chimerism was observed in all BM MNCs as well as within the myeloid fraction, and by 9 weeks this effect was also evident in the c-Kit pos fraction (Figures 2A-2F ). Taken together, these data strongly suggest that miR-22 enhances the self-renewal capacity of HSPCs in vivo.
miR-22 Triggers MDS-like Syndromes and Hematological Malignancies In Vivo
To further test whether increased aberrant hematopoiesis caused by miR-22 overexpression ultimately progresses to malignant hematological disease, we continued to follow up primarily transplanted recipients. Notably, at 12 weeks posttransplantation, recipient mice transplanted with KSL cells from miR-22
;Mx1-Cre donors, but not from Mx1-Cre donors, developed an illness that closely resembled human MDS, as characterized by defective erythroid maturation and anemia, splenomegaly with myeloid infiltration, low white blood cell (WBC) counts, and dysplastic myeloid cells in the peripheral circulation (Figure 3 and Figures S2G and S2H) . To determine whether this disorder is transplantable, the donor-derived KSL cells resorted from primary recipient mice were subjected to a secondary transplantation using fresh competitor cells. In agreement with our earlier results, all secondary recipients developed a lethal hematological disease within 4 weeks after secondary transplantation ( Figure S2I ).
Furthermore, we also monitored disease onset and progression to malignancy in miR-22 transgenic mice. The development of disease similar to that found in our chimeric transplantation model was observed in miR-22 F/+ ;Mx1-Cre mice but not Mx1-Cre littermate controls at 8 months after pIpC administration: the hallmarks of this distress included dysplasia in many lineages including erythroid, myeloid, and platelet; splenomegaly; and an increased number of c-Kit pos undifferentiated blastic cells in the peripheral blood (Figures 4A-4C) . By 16 months after pIpC administration, all miR-22 transgenic mice had developed MDS, affecting multilineage hematopoiesis. Importantly, $13% of mice succumbed to myeloid leukemia as well as T cell lymphoma by 11 months, and all miR-22 transgenic mice suffered from hematological abnormality by 16 months. Finally, $70% of miR-22 transgenic mice developed myeloid leukemia within 2 years ( Figures 4D-4G ).
We also confirmed that the disease was triggered by miR-22 from KSL cells sorted from miR-22-expressing colonies. To this end, miR-22-expressing cells were subjected to consecutive colony replating and at the sixth replating, the residual c-Kit pos Lin neg (KL) cells were transplanted into lethally irradiated recipient mice ( Figure S3A ). Consistent with our in vivo miR-22 transgenic mice data, by 14 weeks after transplantation, recipient mice transplanted with miR-22-expressing cells developed myeloid leukemia, as characterized by increased myeloid blasts in the peripheral blood, defective erythroid maturation and anemia, splenomegaly with the infiltration of myeloid blasts, and increased c-Kit pos blasts in bone marrow ( Figures  S3B-S3H ). Taken together, these data strongly suggest that miR-22 can enhance HSPC function and contribute to leukemia development in vivo.
miR-22 Directly Targets TET2 and Affects the Epigenetic Landscape of the Hematopoietic Compartment In Vivo
To identify relevant molecular targets of miR-22, we next undertook a bioinformatic analysis using TargetScan 6.0 (http://targetscan.org) (Lewis et al., 2005) , microRNA.org (http://www.microrna.org/microrna) (Betel et al., 2008) , and miRBase (http://www.mirbase.org) (Griffiths-Jones et al., 2006) . Among various potential targets, we focused on ten eleven translocation 2 (TET2) as it possesses critically conserved nucleotides indicative of a legitimate target ( Figure S4A ). We then confirmed a direct interaction of miR-22 with the 3 0 UTR region of the TET2 gene by luciferase reporter assay ( Figure S4B and Song et al., 2013) . TET2 is a member of the TET methylcytosine dioxygenase family, which catalyzes the conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC). TET proteins have been implicated in epigenetic reprogramming, embryonic stem cell maintenance, and early development (Ficz et al., 2011; Ito et al., 2010) . Importantly, recurrent TET2 mutations have been identified in a variety of hematological malignancies including MDS, MPN, CMMoL, and AML (AbdelWahab et al., 2009; Delhommeau et al., 2009; Jankowska et al., 2009; Tefferi et al., 2009) . It is noteworthy that the phenotypes elicited by miR-22 overexpression closely phenocopy the inactivation of Tet2 in the hematopoietic system both in vitro and in vivo (Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011) . It has also been documented that Tet2 expression is increased during hematopoietic differentiation, and conversely, that miR-22 is highly expressed in HSPCs while its expression declines in mature cells ( Figure S4C , Moran-Crusio et al., 2011) . We therefore tested whether miR-22 could act as an authentic TET2-targeting miRNA in the hematopoietic compartment by utilizing our conditional transgenic mouse model. To this end, we measured Tet2 expression in the peripheral blood and bone marrow of miR-22
;Mx1-Cre or Mx1-Cre littermate mice at 2-3 weeks after pIpC administration. Importantly, real-time qPCR and western blot analyses revealed a marked reduction in levels of Tet2 mRNA and protein, respectively, in miR-22
;Mx1-Cre mice compared to littermate controls ( Figures 5A, 5B , 5E-5G and Figure S4D) . (legend continued on next page)
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On the basis of these observations, we then sought to determine whether miR-22-mediated TET2 inactivation is sufficient to impact the global epigenetic landscape in blood cells. We therefore analyzed 5-hmC and 5-mC levels in the genomic DNA of miR-22 F/+ ;Mx1-Cre mice. Immunofluorescence and dot blot analyses revealed a drastic (more than 2-fold) reduction in 5-hmC levels and a concomitant increase in 5-mC levels in bone marrow of these mice ( Figures 5C and 5D ), suggesting that changes in an important epigenetic mark (e.g., 5-hmC) may contribute to the ability of miR-22 to affect hematopoiesis and leukemogenesis.
To further understand the consequences of repression of TET2 by miR-22 in hematopoiesis, we next examined the effects of miR-22 overexpression on putative targets of TET2 (Kallin et al., 2012; Ko et al., 2010; Yamazaki et al., 2012 ;Mx1-Cre mice ( Figure 5E and Figure S4E) . Interestingly, absence in myeloma 2 (AIM2) has been reported to have a role in the reduction of cell proliferation by cell cycle arrest and to also be highly methylated in MDS, especially in CMMoL patients with TET2 mutations (Figueroa et al., 2010; Patsos et al., 2010; Yamazaki et al., 2012) . Therefore we hypothesized that its silencing via methylation of the promoter might provide a growth advantage to cancer cells. Additionally, polymorphisms of SP140 (SP140 nuclear body protein) have been found to correlate with chronic lymphoid leukemia, and its hypermethylation has been also demonstrated in CMMoL patients with TET2 mutations, and hence its hypermethylation may influence the risk of leukemogenesis (Di Bernardo et al., 2008; Ko et al., 2010; Yamazaki et al., 2012) . Indeed, we confirmed that the expression of Aim2 and Sp140 was drastically reduced at the levels of mRNA and protein in the bone marrow of miR-22 F/+ ;Mx1-Cre mice compared to littermate controls, and this reduction was associated with an increase in promoter methylation (Figures 5F and 5G and Figure S4F ). Taken together, these results suggest that miR-22 represses TET2 expression and thereby can remodel the epigenetic landscape with global changes in 5-hmC levels and alteration in the expression of putative TET2 target genes including AIM2 and SP140.
miR-22 Enhances Stem Cell Function and Triggers Hematological Transformation through Repression of TET2
Next, we explored the relevance of the crosstalk between miR-22 and TET2 in hematopoiesis and hematological malignancies. To test whether TET2 directly contributes to the function of miR-22 in the hematopoietic compartment, we first infected KSL cells isolated from wild-type mice with a retroviral vector encoding miR-22 and GFP. After the resorting, GFP + KSL cells were additionally infected with a TET2-expressing lentiviral particle. In vitro colony replating and LTC-IC assays demonstrated that the phenotypes caused by miR-22 overexpression in hematopoietic compartment are potently suppressed by ectopic expression of TET2 ( Figures S4G-S4J) . Notably, an in vivo transplantation assay revealed that ectopic expression of TET2 leads to survival advantages for recipient mice transplanted with miR-22-expressing KSL cells ( Figure S4K ). To further examine this interaction, we purified KSL cells from miR-22 transgenic mice and infected them with a retroviral vector encoding Cre recombinase and GFP. After the resorting of GFP + KSL cells, cells were additionally infected with a TET2-expressing lentiviral particle and the resulting phenotypes were analyzed. In vitro colony replating and LTC-IC analyses demonstrated that the oncogenic function of miR-22 was antagonized by ectopic expression of TET2 ( Figures 6A and  6B Figure 6C ). Importantly, the positive survival effect drawn by ectopic expression of TET2 was more pronounced in secondary transplantation ( Figure S5C ). Finally, we purified KSL cells from miR-22 transgenic mice after pIpC administration, infected them with a TET2-expressing lentiviral particle, and evaluated the resulting phenotypes ( Figure 6D ). We found that all the phenotypes elicited by an elevation of miR-22 in vitro and in vivo in hematopoietic compartment, including repression of the expression of Aim2 and Sp140 in bone marrow, were also significantly suppressed by ectopic expression of TET2 ( Figures 6E-6H and Figure S5D ).
Importantly, when we purified KSL cells from primary miR-22 transgenic mice and infected them with TET2 followed by in vivo transplantation together with competitor cells, ectopic expression of TET2 delayed the onset of hematological disorder and was accompanied by significant advantages in disease-free survival ( Figure S5E ). Taken together, these data suggest that TET2 is one of the major targets responsible for the miR-22 proto-oncogenic function in hematopoiesis and the development of hematological malignancies.
miR-22 Decoying Offers Therapeutic Opportunities and Its Overexpression Correlates with the Silencing of TET2 Protein in MDS and AML Patients
Next, we investigated whether the miR-22/TET2 interaction may offer a therapeutic opportunity for the treatment of hematological malignancies. We therefore tested whether inhibition of miR-22 affects TET2 expression and activity, as well as the biology of (E and F) Representative lethal hematological syndromes observed in miR-22 transgenic mice. Representative images of spleens (E, left) and H&E staining (E, right) leukemias. To this end, we inhibited miR-22 in human leukemia cell lines, K562 and U937, both of which express relatively high levels of miR-22 ( Figure S5F , Wang et al., 2012) , by using a miR-22 retroviral sponge or a custom-made locked nucleic acid (LNA; Petersen and Wengel, 2003) miR-22 decoy as the miR-22 sponge. Critically, inhibition of miR-22 in human leukemic cells resulted in a significant reduction in cell proliferation and an elevation of the expression of TET2 and its targets, AIM2 and SP140 ( Figures 6I and 6J and Figures S5G-S5I ). It is worth noting that the U937 cell line harbors phosphatase and tensin homolog (PTEN) mutant with premature termination of coding sequence (Liu et al., 2000) . Hence in this setting the effects observed upon miR-22 decoying are not mediated by the ability of miR-22 to downregulate PTEN expression. In full agreement with these observations, an in vitro colony replating assay revealed that the inhibition of miR-22 by a miR-22 retroviral sponge in KSL cells purified from miR-22 transgenic mice led to a reduction in their colony-forming capability (Figure S5J) . Taken together, these data provide a rationale for the therapeutic potential of targeting miR-22 with LNA miR-22 inhibitors in the treatment of hematological malignancies.
The pathological roles of TET2 in myeloid malignancies have been previously highlighted as its mutations are widely observed in myeloid malignancies and MDS patients. Most of these earlier studies, however, were limited to mutation analysis and found little relationship between the progression of MDS to AML and TET2 expression levels, although the phenotypes of Tet2 knockout mice gave indications to the contrary (Moran-Crusio et al., 2011; Quivoron et al., 2011) . Likewise, emerging evidence demonstrated no significant prognostic association between TET2 mutations in MDS patients and WHO subtypes, the International Prognostic Scoring System (IPSS) score, cytogenetic status, or transformation to AML Smith et al., 2010) .
However, on the basis of our data we hypothesized that a miR-22-dependent reduction in the levels of TET2 might have been overlooked and could play a key role in the development of myeloid malignancies. To test this hypothesis, we investigated a large cohort of patients with MDS by an immunohistochemical analysis. Strikingly, this analysis revealed that $60% of 107 MDS patients analyzed displayed a reduction in the levels of TET2 (36% of 107 MDS patients show Score 1 and 24% show Score 2) and that this reduction was directly correlated with poor survival rates of patients ( Figures 7A and 7B and Figures S6A-S6D) . Importantly, the percentage of blasts distributed in each WHO category of MDS stage was not directly associated with expression level of TET2, but a significant correlation was found between TET2 expression and poor survival rates within each WHO classification, as well as among MDS patients harboring a normal karyotype, suggesting that the poorer survival expectancy linked to TET2 downregulation does not simply reflect confounding factors, such as blast count and cytogenetic karyotype ( Figure 7C and Figures S6E and S6F) . Together, these results suggest that the contribution of TET2 to the pathogenesis of hematological malignancies extends far beyond the initial impact of its mutations.
Importantly, combined in situ hybridization and immunohistochemical analyses revealed that miR-22 expression was directly anticorrelated with the levels of TET2 in a large-cohort data set of MDS patients (n = 107) (Pearson's r = À0.47, p = 2.4 3 10 À7 ): 28% of MDS patients that showed the reduced levels of TET2 (Score 1) also exhibited high miR-22 levels (Score 3) ( Figure 7D and Figure S6G and see also Figure 1A ). Furthermore, because our in vivo analysis demonstrated that miR-22 triggers overt leukemia ( Figure 4G) , we investigated the miR-22/TET2 interactive relationship in AML with multiple lineage dysplasia (MLD) (n = 18). Our combined analyses of in situ hybridization and immunohistochemistry revealed a clear anticorrelation between miR-22 expression and the levels of TET2 (Pearson's r = À0.75, p = 2.9 3 10 À4 ); in addition, 22.2% of AML with MLD patients showing the reduced levels of TET2 (Score 1) displayed a high expression of miR-22 (Score 3) ( Figure 7E ). Western blot and real-time qPCR analyses also corroborated a relationship between miR-22 and TET2 in primary AML patients ( Figure S6H ). Finally, we confirmed these findings by analyzing the expression levels of miR-22 in a very large cohort of AML patients from a previously reported real-time qPCR database (Jongen-Lavrencic et al., 2008) . Here miR-22 was found highly expressed in 58.1% of 214 AML patient samples compared to normal bone marrow from healthy donors (p = 0.028, Figure 7F ). Taken together, these data strongly suggest that aberration of the miR-22-TET2 regulatory network is one of the common events in hematopoietic malignancies.
DISCUSSION
The findings presented in this study point to a number of important conclusions. The first of these is that miR-22 is a powerful regulator of HSPC maintenance and self-renewal. These effects are so pronounced that miR-22-expressing HSPCs out-competed their wild-type counterparts in all the assays that we performed in vivo as well as in vitro. Importantly, in so doing miR-22 also skews hematopoietic differentiation, mainly toward myeloid compartment.
We have also identified miR-22 as a key determinant of the pathogenesis of both MDS and hematological malignancies. Remarkably, miR-22 plays a role in the initiation of MDS as well as full-blown leukemia; hence it exerts a bona fide protooncogenic activity. MDS is a genetically heterogeneous disease and we are only now beginning to fully appreciate its diversity. (legend continued on next page)
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Regulation of TET2 by miR-22 in Hematopoiesis This study will therefore help in the reclassification of subtypes of MDS, and possibly AML, on the basis of miR-22 expression. Furthermore, our comprehensive analysis of MDS patients has identified TET2 protein downregulation as a common event in hemopoietic malignancy (35.5% of total MDS patient samples, and 22.2% of AML samples with MLD, with most of those patients exhibiting high expression of miR-22) and a factor in poor prognosis, findings which directly impact the management and therapeutic decisions for patients with myeloid malignancies. Our findings thus imply that the contribution of TET2 to the pathogenesis of myeloid malignancies could be related to more than its mutations and identify the deregulation of the miR-22-TET2 pathway as one of the most frequent events in hematological malignancies. Importantly, they also provide a compelling rationale for targeted therapies that impact the mechanisms of regulation responsible for the control of TET2 levels (e.g., through miR-22 decoying).
We show that miR-22 negatively regulates the expression of TET2 and that its overexpression closely phenocopies, both in vitro and in vivo, many of the characteristics observed upon inactivation of TET2 ( Figure 7G ). Extensive mouse modeling efforts support these similarities both in our current study and in other Tet2-related studies (Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011) . Furthermore, our comprehensive analyses of a large cohort of MDS and AML patients likewise have demonstrated this antagonistic crosstalk.
miR-22 also appears to exert a tumor-promoting role in other tissues, including mammary glands, through its ability to suppress the expression of other TET family members such as TET1 and TET3 ( Figure S4D and Song et al., 2013) . Thus, miR-22 contributes to inactivation of TET2 and other TET family members in tumorigenesis, representing a tumorigeneic pathway in addition to the more familiar ones of TET2 and TET family mutations and deletions.
We previously demonstrated that miR-22 also targets the PTEN tumor suppressor (Poliseno et al., 2010) . Pten loss has also been implicated in the pathogenesis of hematological malignancies (Yilmaz et al., 2006; Zhang et al., 2006) . However, miR-22 through TET2 regulation can bestow to hemopoietic cells further competitive advantage as also supported by the fact that miR-22 decoying suppresses proliferation even in a PTEN mutant setting ( Figure S5I ). This may in turn explain the potent proto-oncogenic activity of miR-22. Indeed, there are several intriguing phenotypical differences between Pten F/F ;Mx1-Cre and miR-22
;Mx1-Cre mouse models that could illuminate a unique and powerful role exerted by miR-22 in leukemogenesis. First, miR-22 increased the ability of HSCs to repopulate, which was then followed by leukemia development, whereas loss of Pten resulted in the exhaustion of normal HSCs. In addition, while Pten loss induces short-term expansion in HSCs through excessive cell cycle entry followed by exhaustion, no significant alteration in the stem cell compartment was observed at 2-3 weeks after the introduction of miR-22 ( Figure S7 ). Additionally, while loss of Pten in HSCs is known to lead to MPN-like disease followed by leukemia development, hematological dysplasia with ineffective hematopoiesis is one of the main phenotypes caused by miR-22 expression, with bicytopenia or pancytopenia observed in miR-22 transgenic mice. Furthermore, although HSCs from Pten F/+ ;Mx1-Cre mice are known to be transplantable, the recipients do not develop hematopoietic syndromes (Yilmaz et al., 2006) . In contrast, recipient mice transplanted with HSCs purified from miR-22
;Mx1-Cre mice developed aberrant hematopoiesis followed by MDS and leukemia. Hence, the ability of miR-22 to concomitantly downregulate TET2 and PTEN provides it a unique mode of action and confers on it the ability to overcome PTEN-loss-driven stem cell exhaustion while favoring MDS development and leukemogenesis. This in turn raises the possibility that concomitant silencing of TET2 and PTEN by miR-22 could represent a powerful event underlying the pathogenesis of human cancer, as it may overcome the fail-safe mechanisms elicited by loss of PTEN (Berger et al., 2011) .
Finally, since the technology to inhibit miRNAs for therapy is rapidly evolving (Elmé n et al., 2008; Stenvang et al., 2008) , this will impact treatment options for a range of diseases and disorders in the years to come. Indeed, LNA-based miRNA decoying has already come of age for the treatment of hepatitis C (Lanford et al., 2010) and may prove very effective for the treatment of (C) TET2 attenuates the hematopoietic malignancies induced by miR-22 overexpression. KSL cells sorted from miR-22 F/+ mice were infected with Cre-GFP or GFP control vector before TET2 infection, and 1,500 GFP + KSL cells were transplanted into recipient mice with 2.0 3 10 5 Ly45.1 competitor bone marrow mononuclear cells (BM MNCs). Disease-free survival of recipient mice was examined by Kaplan-Meier survival curves. Log-rank test was used to generate p values. (D) Overview of the experimental design for introduction of TET2 into KSL cells from miR-22 transgenic mice. KSL cells purified from miR-22 transgenic mice were subjected to infection with TET2-expressing vector, and their characteristics were evaluated in vivo and in vitro. (E) Colony-forming capacity of miR-22 transgenic progenitor cells is attenuated by ectopic expression of TET2. Two weeks after pIpC administration, sorted KSL cells from miR-22 F/+ ;Mx1-Cre mice were infected with TET2-expressing vector and resorted KSL cells were then subjected to incubation in semisolid medium.
The resulting colony numbers were scored in three independent littermate pairs in the indicated platings (n = 3). N.D., nondetectable.
(F and G) Ectopic expression of TET2 causes a reduction in LTC-IC capacity of miR-22 transgenic progenitor cells. TET2-infected KSL cells from miR-22 F/+ ;Mx1-Cre mice or littermate controls, as shown in Figure 6D , were cocultured with stromal cells for the indicated weeks. Maintained KSL cells were evaluated 2 weeks after coculture (n = 3) (F). At the indicated times after coculture, the capacity of colony formation was also determined in semisolid medium (n = 3) (G). Insets represent TET2 staining in blasts (arrow with B) with a high magnification. Scoring the expression levels of TET2 in blasts was performed as described in Supplemental Experimental Procedures (right). The data were analyzed by Chi-square test. r, Pearson's r. Scale bars, 60 mm.
(B) Downregulation of TET2 levels correlates with poor survival rates of human MDS patients. Overall survival of patients that express low TET2 (TET2 Score 1, n = 38, red) or high TET2 (TET2 Score 2 or 3, n = 69, blue) is shown. p value was generated by a log-rank test.
(C) Survival rates of low TET2 (Score 1) and high TET2 (Score 2 or 3) patients with RA (left), RAEB-1 (middle), and RAEB-2 (right). Survival rate of the p value was generated by a log-rank test.
(legend continued on next page)
Regulation of TET2 by miR-22 in Hematopoiesis blood-borne diseases . The data presented in this study thus support the notion that an LNA-based therapeutic targeting of miR-22 may represent an effective strategy for TET2 reactivation as a treatment modality for incurable diseases such as MDS and leukemia.
EXPERIMENTAL PROCEDURES Mice
The details of generation of miR-22 transgenic mice are described in the Supplemental Experimental Procedures. C57BL/6 mice (B6-CD45.2) and C57BL/6 mice congenic for the CD45 locus (B6-CD45.1) were purchased from The Jackson Laboratory and used as recipients in the transplantation assay.
Real-Time qPCR
The details of RNA isolation and real-time qPCR analysis are described in the Supplemental Experimental Procedures.
Immunofluorescence
Cells were fixed and stained as described (Ko et al., 2010) . The details of staining of cells and the sources of antibodies used are also described in the Supplemental Experimental Procedures.
Flow Cytometry
The sources of antibodies used for flow cytometric analysis are described in the Supplemental Experimental Procedures.
Long-Term Cultures and In Vitro Colony-Forming Assays
The details of colony replating assays are described in the Supplemental Experimental Procedures.
Competitive Reconstitution Assay
The details of competitive reconstitution assay are described in the Supplemental Experimental Procedures.
Human Sample Analysis
Human patient samples were analyzed as described in detail in the Supplemental Experimental Procedures. This study was approved by the Institutional Review Board waiver and Human Tissue Utilization Committee, and clinical and hematological data were recorded after patients provided their informed consent in accordance with the Declaration of Helsinki.
miRNA In Situ Hybridization
The details of in situ hybridization analysis for miR-22 are described in the Supplemental Experimental Procedures.
Immunohistochemistry
The details of immunohistochemical analysis are described in the Supplemental Experimental Procedures.
Dynamic Transcriptome Analysis
The details of dynamic transcriptome analysis are described in the Supplemental Experimental Procedures.
Methylation-Specific PCR DNA methylation status of Sp140 in purified KSL cells (or Lin neg cells) was examined by the methylation-specific PCR with genomic DNA treated with sodium bisulfite using the EZ DNA Methylation-Direct kit (Zymo Research). Primer sequences were previously described (Yamazaki et al., 2012) . b-actin was used as an internal control of genomic DNA.
Luciferase Reporter Assay
The details of the luciferase reporter assay are described in the Supplemental Experimental Procedures.
Statistical Analysis
Student's t test was utilized to determine statistical significance unless otherwise specified. p < 0.05 was considered statistically significant. 
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